Multiple sclerosis and related disorders · 2025
MOGAD treatment outcomes and relapse characteristics: Real world experience from a Low-Middle income country.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jain Kshiteeja, Dhamija Kamakshi, Holla Vikram V, Thennarasu K, Bhat Maya, Mahadevan Anita, Netravathi M
Аннотация
BACKGROUND: Myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) is a distinct immune-mediated neurological disorder requiring specific therapies. The study aims to evaluate relapse patterns, predictors, and compare relapse rates and disability outcomes of common immunotherapies in Indian MOGAD patients.
METHODOLOGY: We conducted an observational cohort study of 155 pediatric and adult MOGAD patients, classifying phenotypes into optic neuritis (ON), myelitis (MYE), acute disseminated encephalomyelitis (ADEM), opticomyelitis (OM), brainstem (BS) and others. Annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) scores were calculated pre- and on-treatment for azathioprine (Imuran), mycophenolate mofetil (CellCept) and rituximab. Kaplan-Meier survival analysis and Cox proportional hazards regression identified predictors of relapse.
RESULTS: ON (39.4 %) was the most common phenotype though pediatric patients had significantly more ADEM cases (p < 0.001). Over half experienced relapses, more in pediatric (p = 0.011), and ADEM patients (p < 0.001). More frequent relapses correlated with higher EDSS scores at last follow-up (rho=0.442, p < 0.001). MYE patients had the longest relapse-free survival (median 132 months, p < 0.001). Mean(SD) ARR reduced from 1.12(2.00) to 0.26(0.49) with azathioprine (Imuran), from 1.08(2.43) to 0.11(0.54) with MMF (p = 0.006) and from 1.23(2.30) to 0.71(2.01) with rituximab (p = 0.007). EDSS scores significantly improved with all therapies (p < 0.001-0.007). Higher baseline ARR predicted relapse after treatment initiation (HR 1.23[95 % CI,1.05-1.43], p = 0.009), while myelitis at onset was protective (HR 0.22[95 % CI,0.05-0.95], p = 0.042).
CONCLUSION: Over half of MOGAD patients relapse, and increased relapses correlate with greater long-term disability. Myelitis at onset is associated with lower relapse risk. Conventional first-line immunotherapies are effective across medications, phenotypes and age groups.
METHODOLOGY: We conducted an observational cohort study of 155 pediatric and adult MOGAD patients, classifying phenotypes into optic neuritis (ON), myelitis (MYE), acute disseminated encephalomyelitis (ADEM), opticomyelitis (OM), brainstem (BS) and others. Annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) scores were calculated pre- and on-treatment for azathioprine (Imuran), mycophenolate mofetil (CellCept) and rituximab. Kaplan-Meier survival analysis and Cox proportional hazards regression identified predictors of relapse.
RESULTS: ON (39.4 %) was the most common phenotype though pediatric patients had significantly more ADEM cases (p < 0.001). Over half experienced relapses, more in pediatric (p = 0.011), and ADEM patients (p < 0.001). More frequent relapses correlated with higher EDSS scores at last follow-up (rho=0.442, p < 0.001). MYE patients had the longest relapse-free survival (median 132 months, p < 0.001). Mean(SD) ARR reduced from 1.12(2.00) to 0.26(0.49) with azathioprine (Imuran), from 1.08(2.43) to 0.11(0.54) with MMF (p = 0.006) and from 1.23(2.30) to 0.71(2.01) with rituximab (p = 0.007). EDSS scores significantly improved with all therapies (p < 0.001-0.007). Higher baseline ARR predicted relapse after treatment initiation (HR 1.23[95 % CI,1.05-1.43], p = 0.009), while myelitis at onset was protective (HR 0.22[95 % CI,0.05-0.95], p = 0.042).
CONCLUSION: Over half of MOGAD patients relapse, and increased relapses correlate with greater long-term disability. Myelitis at onset is associated with lower relapse risk. Conventional first-line immunotherapies are effective across medications, phenotypes and age groups.